Skip to main content
Laurus Labs Limited logo

Laurus Labs Limited — Investor Relations & Filings

Ticker · LAURUSLABS ISIN · INE947Q01028 LEI · 335800S8HO8QRYP3VQ26 BSE.NS Manufacturing
Open in API
Filings indexed 707 across all filing types
Latest filing 2019-11-21 Regulatory Filings
Country IN India
Listing BSE.NS LAURUSLABS

About Laurus Labs Limited

https://www.lauruslabs.com/

Laurus Labs Limited is a research-driven organization focused on the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms (FDF), and specialized synthesis services. The company operates across several key therapeutic areas, including anti-retroviral (ARV), oncology, cardiovascular, and anti-diabetic treatments. Through its contract development and manufacturing organization (CDMO) division, it provides integrated drug development solutions to global partners. The company also maintains a biotechnology segment dedicated to recombinant products. Leveraging advanced research and development capabilities alongside large-scale manufacturing infrastructure, the firm emphasizes process chemistry innovation and cost-efficient production to serve diverse global healthcare markets.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the completion of a USFDA Pre Approval Inspection (PAI) for an API manufactured at Laurus Labs' units. It contains no financial data, no detailed report, no voting results, no management changes, no earnings information, or other regulatory filings. It is a regulatory announcement about an inspection outcome, not a financial or governance report. The document length is short (2835 characters) and it is clearly a press release. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2019-11-21 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the completion of a USFDA inspection at Laurus Labs' manufacturing facility. It contains no financial data, no detailed report, and is relatively short (2781 characters). It is an announcement of an event (inspection completion) rather than a formal regulatory filing or financial report. It does not fit into categories like Annual Report, Interim Report, or Audit Report. It is not a voting result, management change, or earnings release. The best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2019-11-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of the Laurus Labs Q2 FY2020 Earnings Conference Call held on November 1, 2019. It includes detailed discussions of quarterly financial results, business segment performance, management commentary, and a Q&A session with analysts. The presence of a moderator, management speakers, and analyst questions confirms this is a full earnings call transcript. The content focuses on quarterly financial performance and outlook, which aligns with the definition of a Call Transcript (CT).
2019-11-07 English
Related Party Transactions
Management Reports Classification · 85% confidence The document contains detailed disclosures about related party transactions, including names and relationships of key management personnel and their relatives, as well as financial transactions during a half-year period ending September 30, 2019. This type of detailed management and financial explanation aligns with Management Reports (MDA), which provide management's detailed explanation of financial results, business trends, and outlook. The document is not a full annual or interim report but focuses on management-related financial disclosures. The document length is relatively short (2084 characters), but it contains substantive financial data related to management and related parties, so it is not a mere announcement or certification. Therefore, the best fit is Management Reports (MDA).
2019-11-06 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is an investor presentation dated October 31, 2019, related to the unaudited financial results for the quarter and half-year ended September 30, 2019. It includes detailed business snapshots, growth strategies, product portfolios, filings status, and manufacturing infrastructure. The text explicitly mentions it is an "Investors/Analysts Presentation" and contains forward-looking statements, business overview, and market strategy, which are typical contents of an investor presentation. There is no indication that this is a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a brief earnings release or a regulatory filing. The length and content confirm it is a detailed presentation for investors focusing on financials, strategy, and market position, matching the definition of an Investor Presentation (IP).
2019-10-31 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated October 31, 2019, announcing the Q2 and H1 FY20 financial results of Laurus Labs Limited. It contains summarized financial highlights such as revenue, EBITDA, PAT, and EPS for the quarter and half-year periods, along with management commentary on business performance and regulatory updates. The document is approximately 6,677 characters long, which is sufficient to include substantive financial data and analysis. It is not a full annual report but a quarterly earnings announcement with key financial metrics and business commentary. Therefore, it fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights only. Q2 2020
2019-10-31 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.